Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial

Authors：Jingen Li; Zhuye Gao; Lijing Zhang; Shengyao Li; Qiaoning Yang; Qinghua Shang; Xiang Gao; Hua Qu; Jie Gao; Lixiao Shi; Yue Liu; Jianpeng Du; Hao Xu; Dazhuo Shi

Source：Complementary Therapies in Medicine, 2019, 47(C): 102209.

DOI：10.1016/j.ctim.2019.102209

• Stable coronary artery disease
• Qing-Xin-Jie-Yu Granule
• Chinese herbal medicine
• Cardiovascular events
• Randomized controlled trial

Background and aim(#br)Despite optimal secondary preventive treatment, patients with stable coronary artery disease (SCAD) remain at high risk of cardiovascular events. This multicenter, double-blinded, randomized trial sought to determine whether the addition of Qing-Xin-Jie-Yu Granule (QXJYG), a traditional Chinese medicine prescription, to standard therapy would further reduce risk of cardiovascular events in patients with SCAD.(#br)Methods(#br)A total of 1500 patients with documented SCAD were randomly assigned in a 1:1 ratio to QXJYG or placebo for 6 months, and followed up for another 6 months. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction (MI) and coronary revascularization. Near the end of the trial, but before unblinding, a commonly used composite ‘hard’ endpoint composed of cardiovascular death, nonfatal myocardial infarction and ischemic stroke was additionally analyzed.(#br)Results(#br)During a median follow-up of 12 months, no significant...